FIELD: medicine.
SUBSTANCE: invention relates to a pharmaceutical composition for the treatment of hyperphosphataemia, use of the composition, method of production thereof and to a tablet for the treatment of hyperphosphataemia. Pharmaceutical composition comprises iron oxy-hydroxide in an amount of 10 to 80 % in a form suitable for oral administration, which comprises a mixture of native and pregelatinized starch.
EFFECT: implementation of the invention will make it possible to obtain an iron oxy-hydroxide composition in the form of a high-dosage oral system capable of rapid disintegration.
31 cl, 8 ex, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITIONS | 2008 |
|
RU2493831C2 |
| PHOSPHATE ADSORBENT BASED ON IRON (III) COMPOUNDS AND CARBOHYDRATES | 2007 |
|
RU2447933C2 |
| CORTICOSTEROID-CONTAINING ORALLY DISINTEGRATING TABLET COMPOSITIONS FOR TREATING EOSINOPHILIC ESOPHAGITIS | 2014 |
|
RU2678695C2 |
| PHARMACEUTICAL COPMOSITIONS DISSOLVING IN ORAL CAVITY | 2005 |
|
RU2405541C2 |
| ORALLY DISINTEGRATING TABLET TEMAZEPAM COMPOSITIONS | 2008 |
|
RU2524638C2 |
| SOLID NICOTINE-CONTAINING DOSAGE FORM WITH REDUCED UNPLEASANT ORGANOLEPTIC IMPACT | 2013 |
|
RU2623018C2 |
| SUBLINGUAL COATED TABLET | 2006 |
|
RU2403043C2 |
| TABLET CONTAINING A SEPARATE BINDING SUBSTANCE AND ERYTHRITE | 2017 |
|
RU2736072C1 |
| BIODEGRADABLE SYSTEM OF TRANSMUCOSAL DELIVERY OF DROTAVERIN | 2017 |
|
RU2699808C2 |
| DOSAGE FORM FOR RELEASING DROTAVERINE IN ORAL CAVITY | 2019 |
|
RU2729659C1 |
